Your browser doesn't support javascript.
loading
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz, Emre; Ertürk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Hizal, Mutlu; Arikan, Rukiye; Arslan, Çagatay; Taban, Hakan; Küçükarda, Ahmet; Öztas, Nihan Sentürk; Sever, Özlem Nuray; Uçar, Gökhan; Can, Orçun; Sendur, Mehmet Ali; Demirci, Umut; Kiliçkap, Saadettin; Çiçin, Irfan; Öksüzoglu, Berna; Özgüroglu, Mustafa; Ürün, Yüksel.
Affiliation
  • Yekedüz E; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.
  • Ertürk I; Cancer Research Institute, Ankara University, Ankara, 06590, Turkey.
  • Tural D; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey.
  • Karadurmus N; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training & Research Hospital, University of Health Sciences, Istanbul, 34147, Turkey.
  • Karakaya S; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey.
  • Hizal M; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey.
  • Arikan R; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey.
  • Arslan Ç; Department of Medical Oncology, Marmara University, Istanbul, 34899, Turkey.
  • Taban H; Department of Medical Oncology, Izmir University of Economics, Izmir, 35575, Turkey.
  • Küçükarda A; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.
  • Öztas NS; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey.
  • Sever ÖN; Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, 34098, Turkey.
  • Uçar G; Department of Medical Oncology, Gaziantep University, Gaziantep, 27070, Turkey.
  • Can O; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey.
  • Sendur MA; Department of Medical Oncology, Prof. Dr. Cemil Tasçioglu City Hospital, University of Health Sciences, Istanbul, 34384, Turkey.
  • Demirci U; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, 06800, Turkey.
  • Kiliçkap S; Department of Medical Oncology, Üsküdar University, Memorial Ankara Hospital, Ankara, 06520, Turkey.
  • Çiçin I; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.
  • Öksüzoglu B; Department of Medical Oncology, Istinye University, Istanbul, 34010, Turkey.
  • Özgüroglu M; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey.
  • Ürün Y; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey.
Future Oncol ; 17(35): 4861-4869, 2021 12.
Article in En | MEDLINE | ID: mdl-34726480
Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Molecular Targeted Therapy / Nivolumab / Immune Checkpoint Inhibitors / Kidney Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: Turkey
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Molecular Targeted Therapy / Nivolumab / Immune Checkpoint Inhibitors / Kidney Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: Turkey